Ultragenyx to sell rare pediatric disease priority review voucher for $203 million

Bitget2026/10/14 12:32

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Ultragenyx signed a definitive agreement to sell a Rare Pediatric Disease Priority Review Voucher for USD 203 million.
The voucher was awarded on FDA clearance of FAYUVI (UX111) for mucopolysaccharidosis type IIIA, also known as Sanfilippo syndrome Type A.
Closing remains subject to customary conditions, including expiration of the Hart-Scott-Rodino waiting period.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ultragenyx Pharmaceutical Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610140830PRIMZONEFULLFEED9845228) on October 14, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Ultragenyx to sell rare pediatric disease priority review voucher for $203 million

You may also like

Crypto prices